Unknown

Dataset Information

0

A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-? Signaling and Activation of cAMP/PKA Signaling.


ABSTRACT: Phosphodiesterase (PDE) inhibitors are currently a widespread and extensively studied group of anti-inflammatory and anti-fibrotic compounds which may find use in the treatment of numerous lung diseases, including asthma and chronic obstructive pulmonary disease. Several PDE inhibitors are currently in clinical development, and some of them, e.g., roflumilast, are already recommended for clinical use. Due to numerous reports indicating that elevated intracellular cAMP levels may contribute to the alleviation of inflammation and airway fibrosis, new and effective PDE inhibitors are constantly being sought. Recently, a group of 7,8-disubstituted purine-2,6-dione derivatives, representing a novel and prominent pan-PDE inhibitors has been synthesized. Some of them were reported to modulate transient receptor potential ankyrin 1 (TRPA1) ion channels as well. In this study, we investigated the effect of selected derivatives (832-a pan-PDE inhibitor, 869-a TRPA1 modulator, and 145-a pan-PDE inhibitor and a weak TRPA1 modulator) on cellular responses related to airway remodeling using MRC-5 human lung fibroblasts. Compound 145 exerted the most considerable effect in limiting fibroblast to myofibroblasts transition (FMT) as well as proliferation, migration, and contraction. The effect of this compound appeared to depend mainly on its strong PDE inhibitory properties, and not on its effects on TRPA1 modulation. The strong anti-remodeling effects of 145 required activation of the cAMP/protein kinase A (PKA)/cAMP response element-binding protein (CREB) pathway leading to inhibition of transforming growth factor type ?1 (TGF-?1) and Smad-dependent signaling in MRC-5 cells. These data suggest that the TGF-? pathway is a major target for PDE inhibitors leading to inhibitory effects on cell responses involved in airway remodeling. These potent, pan-PDE inhibitors from the group of 7,8-disubstituted purine-2,6-dione derivatives, thus represent promising anti-remodeling drug candidates for further research.

SUBMITTER: Wojcik-Pszczola K 

PROVIDER: S-EPMC7312375 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-β Signaling and Activation of cAMP/PKA Signaling.

Wójcik-Pszczoła Katarzyna K   Chłoń-Rzepa Grażyna G   Jankowska Agnieszka A   Ślusarczyk Marietta M   Ferdek Paweł E PE   Kusiak Agnieszka A AA   Świerczek Artur A   Pociecha Krzysztof K   Koczurkiewicz-Adamczyk Paulina P   Wyska Elżbieta E   Pękala Elżbieta E   Gosens Reinoud R  

International journal of molecular sciences 20200603 11


Phosphodiesterase (PDE) inhibitors are currently a widespread and extensively studied group of anti-inflammatory and anti-fibrotic compounds which may find use in the treatment of numerous lung diseases, including asthma and chronic obstructive pulmonary disease. Several PDE inhibitors are currently in clinical development, and some of them, e.g., roflumilast, are already recommended for clinical use. Due to numerous reports indicating that elevated intracellular cAMP levels may contribute to th  ...[more]

Similar Datasets

| S-EPMC4167538 | biostudies-literature
| S-EPMC5479052 | biostudies-literature
| S-EPMC4576172 | biostudies-literature
| S-EPMC8328970 | biostudies-literature
| S-EPMC1765484 | biostudies-literature
| S-EPMC4948347 | biostudies-literature
| S-EPMC7684908 | biostudies-literature
| S-EPMC8146537 | biostudies-literature
| S-EPMC8635787 | biostudies-literature
| S-EPMC3073414 | biostudies-other